Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas

Cancer Research

Volumn 65, Issue 15, 2005, Pages 6726-6733

  Viapiano, Mariano S ^a   Bi, Wenya Linda ^a   Piepmeier, Joseph ^a   Hockfield, Susan ^a   Matthews, Russell T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREVICAN; SCLEROPROTEIN;

ARTICLE; BRAIN TISSUE; CANCER INVASION; CONTROLLED STUDY; GLIOBLASTOMA; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROPATHOLOGY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ANIMALS; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL MEMBRANE; FEMALE; GLIOMA; GLYCOSYLATION; HUMANS; LECTINS, C-TYPE; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PROTEIN ISOFORMS; PROTEOCHONDROITIN SULFATES; RATS; TRANSFECTION;

EID: 23044475300     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0585     Document Type: Article

References (35)

1. Kleihues P, Cavenee WK. WHO classification of tumours: pathology and genetics of tumours of the nervous system. Lyon: IARC Press; 2000.
2. Berens ME, Giese A. "...those left behind." Biology and oncology of invasive glioma cells. Neoplasia 1999;1:208-19.
3. Pilkington GJ. The paradox of neoplastic glial cell invasion of the brain and apparent metastatic failure. Anticancer Res 1997;17:4103-5.
4. Subramanian A, Harris A, Piggott K, Shieff C, Bradford R. Metastasis to and from the central nervous system: the "relatively protected site." Lancet Oncol 2002;3:498-507.
5. Celio MR, Blumcke I. Perineuronal nets: a specialized form of extracellular matrix in the adult nervous system. Brain Res Brain Res Rev 1994;19:128-45.
6. Gladson CL. The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 1999;58:1029-40.
7. Akiyama Y, Jung S, Salhia B, et al. Hyaluronate receptors mediating glioma cell migration and proliferation. J Neurooncol 2001;53:115-27.
8. Goldbrunner RH, Bernstein JJ, Tonn JC. Cell-extracellular matrix interaction in glioma invasion. Acta Neurochir (Wien) 1999;141:295-305; discussion 304-5.
9. Novak U, Kaye AH. Extracellular matrix and the brain: components and function. J Clin Neurosci 2000; 7:280-90.
10. Gary SC, Kelly GM, Hockfield S. BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility. Curr Opin Neurobiol 1998;8:576-81.
11. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 2000;57:276-89.
12. Jaworski DM, Kelly GM, Piepmeier JM, Hockfield S. BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res 1996;56:2293-8.
13. Gary SC, Zerillo CA, Chiang VL, Gave JU Gray G, Hockfield S. cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma. Gene 2000;256:139-47.
14. Boon K, Osorio EC, Greenhut SF, et al. An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A 2002;99:11287-92.
15. Zhang H, Kelly G, Zerillo C, Jaworski DM, Hockfield S. Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion in vivo. J Neurosci 1998;18:2370-6.
16. Nutt CL, Zerillo CA, Kelly GM, Hockfield S. Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. Cancer Res 2001;61:7056-9.
17. Seidenbecher CI, Richter K, Rauch U, Fassler R, Garner CC, Gundelfinger ED. Brevican, a chondroitin sulfate proteoglycan of rat brain, occurs as secreted and cell surface glycosylphosphatidylinositol-anchored isoforms. J Biol Chem 1995;270:27206-12.
18. Matthews RT, Gary SC, Zerillo C, et al. Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J Biol Chem 2000;275: 22695-703.
19. Nakamura H, Fujii Y, Inoki I, et al. Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites. J Biol Chem 2000;275:38885-90.
20. Viapiano MS, Matthews RT, Hockfield S. A novel membrane-associated glycovariant of BEHAB/Brevican is up-regulated during rat brain development and in a rat model of invasive glioma. J Biol Chem 2003;278: 33239-47.
21. Bartolomei JC, Christopher S, Vives K, Spencer DD, Piepmeier JM. Low-grade gliomas of chronic epilepsy: a distinct clinical and pathological entity. J Neurooncol 1997;34:79-84.
22. Luyken C, Blumcke I, Fimmers R, et al. The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 2003;44:822-30.
23. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. Glia 1995;15:244-56.
24. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001;491: 369-402.
25. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997;14:569-76.
26. Seyfried TN. Perspectives on brain tumor formation involving macrophages, glia, and neural stem cells. Perspect Biol Med 2001;44:263-82.
27. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 2002;99:10231-3.
28. Ono M, Hakomori S. Glycosylation defining cancer cell motility and invasiveness. Glycoconj J 2004;20:71-8.
29. Matthews RT, Kelly GM, Zerillo CA, Gray G, Tiemeyer M, Hockfield S. Aggrecan glycoforms contribute to the molecular heterogeneity of perineuronal nets. J Neurosci 2002;22:7536-47.
30. Bandtlow CE, Zimmermann DR. Proteoglycans in the developing brain: new conceptual insights for old proteins. Physiol Rev 2000;80:1267-90.
31. Properzi F, Fawcett JW. Proteoglycans and brain repair. News Physiol Sci 2004;19:33-8.
32. Gross N, Balmas K, Beretta Brognara C. Role of CD44H carbohydrate structure in neuroblastoma adhesive properties. Med Pediatr Oncol 2001;36:139-41.
33. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96.
34. Goetz C, Riva P, Poepperl G, et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol 2003;62:321-8.
35. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004;3:430-46.